Ruth Steinberg

Ruth Steinberg

Auto-generated profile, based on publicly available information

Ruth Steinberg

Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
RSRuth Steinberg
Ruth Steinberg
AOAndrea Origi
Andrea Origi
ANAna Natriashvili
Ana Natriashvili
PSPinku Sarmah
Pinku Sarmah
MLMariya Licheva
Mariya Licheva
HKHans Georg Koch
Hans Georg Koch
Small membrane proteins represent a largely unexplored yet abundant class of proteins in pro- and eukaryotes. They essentially consist of a single transmembrane domain and are associated with stress response mechanisms in bacteria. How these proteins are inserted into the bacterial membrane is unknown. Our study revealed that in Escherichia coli, the 27-amino-acid-long model protein YohP is recognized by the signal recognition particle (SRP), as indicated by in vivo and in vitro site-directed cross-linking. Cross-links to SRP were also observed for a second small membrane protein, the 33-amino-acid-long YkgR. However, in contrast to the canonical cotranslational recognition by SRP, SRP was found to bind to YohP posttranslationally. In vitro protein transport assays in the presence of a SecY inhibitor and proteoliposome studies demonstrated that SRP and its receptor FtsY are essential for the posttranslational membrane insertion of YohP by either the SecYEG translocon or by the YidC insertase. Furthermore, our data showed that the yohP mRNA localized preferentially and translation-independently to the bacterial membrane in vivo. In summary, our data revealed that YohP engages an unique SRP-dependent posttranslational insertion pathway that is likely preceded by an mRNA targeting step. This further highlights the enormous plasticity of bacterial protein transport machineries.

10 January 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
RSRuth Steinberg
Ruth Steinberg
VMVéronique Msc Marty
Véronique Msc Marty
IKInsa Korten
Insa Korten
CAChristoph Aebi
Christoph Aebi
PLPhilipp Latzin
Philipp Latzin
PAPhilipp Kwame Abayie Agyeman
Philipp Kwame Abayie Agyeman
We assessed human metapneumovirus infections in children hospitalized between 2011 and 2023 and compared the strongest pre- and postpandemic seasons. After the COVID-19 pandemic, we observed offseason cases and loss of the alternating pattern of the human metapneumovirus season magnitude. Incidence rate ratio of 0- to 11-month-old versus 12- to 23-month-old children was 2.1 (95% CI: 1.0–4.8) before and 1.3 (95% CI: 0.6–2.9) after the pandemic.

15 October 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
RSRuth Steinberg
Ruth Steinberg
AMAlexander Moeller
Alexander Moeller
AGAmanda Gisler
Amanda Gisler
NMNadja Mostacci
Nadja Mostacci
MHMarkus Hilty
Markus Hilty
JUJakob Usemann
Jakob Usemann
Triple modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves lung function and impacts upon the respiratory microbiome in people with Cystic fibrosis (pwCF) with advanced lung disease. However, adolescents with cystic fibrosis (CF) are less colonized with bacterial pathogens than adult pwCF but their microbiota already differs from healthy individuals. The aim of this study was to longitudinally analyze the impact of ETI on the respiratory metagenome in adolescents with predominantly mild CF lung disease. In this prospective observational study, we included pwCF aged 12-20 years with at least one F508del mutation, who collected oropharyngeal swabs before and after initiation of ETI therapy twice per week to biweekly over three months. We performed whole metagenome shotgun sequencing, followed by host DNA filtering and taxonomic profiling. We used linear and additive mixed effects models adjusted for known confounders and corrected for multiple testing to study longitudinal development of the microbiome. We analyzed bacterial diversity, abundance, and strain-level phylogeny. We analyzed the metagenomic data of 297 swabs of 20 pwCF. Microbiome composition changed after initiation of ETI therapy. We observed a slight diversification of the microbiome over time (Inv Simpson, Coef 0.085, 95 %CI 0.003, 0.17, p = 0.04). Strain-level analysis and clustering showed that strain retention of the most frequent bacterial species is predominant even during ETI therapy. During three months of ETI therapy, commensal bacteria increased, which may help to prevent overgrowth of bacterial pathogens.

21 December 2023 in mSystems
Verified
Journal Article
Open access
NMNadja Mostacci
Nadja Mostacci
TWTsering Monika Wüthrich
Tsering Monika Wüthrich
LSLéa Siegwald
Léa Siegwald
SKSilas Kieser
Silas Kieser
RSRuth Steinberg
Ruth Steinberg
MHMarkus Hilty
Markus Hilty
Shotgun metagenomic sequencing has the potential to provide bacterial strain-level resolution which is of key importance to tackle a host of clinical questions. While bioinformatic tools that achieve strain-level resolution are available, thorough benchmarking is needed to validate their use for less investigated and low biomass microbiomes like those from the upper respiratory tract. We analyzed a previously published data set of longitudinally collected nasopharyngeal samples from Bangladeshi infants (Microbiota and Health study) and a novel data set of oropharyngeal samples from Swiss children with cystic fibrosis. Data from bacterial cultures were used for benchmarking the parameters of StrainPhlAn 3, a bioinformatic tool designed for strain-level resolution. In addition, StrainPhlAn 3 results were compared with metagenomic assemblies derived from StrainGE and newly derived whole-genome sequencing data. After optimizing the analytical parameters, we compared StrainPhlAn 3 results to culture gold standard methods and achieved sensitivity values of 87% ( Streptococcus pneumoniae ), 80% ( Moraxella catarrhalis ), 75% ( Haemophilus influenzae ), and 57% ( Staphylococcus aureus ) for 420 nasopharyngeal and 75% ( H. influenzae ) and 46% ( S. aureus ) for 260 oropharyngeal samples. Comparing the phylogenetic tree of the core genome of 50 S . aureus isolates with a corresponding marker gene tree generated by StrainPhlAn 3 revealed a striking similarity in tree topology for all but three samples indicating adequate strain resolution. In conclusion, a comparison of StrainPhlAn 3 results to data from bacterial cultures revealed that strain-level tracking of the respiratory microbiome is feasible despite the high content of host DNA when parameters are carefully optimized to fit low biomass microbiomes. IMPORTANCE: The usage of 16S rRNA gene sequencing has become the state-of-the-art method for the characterization of the microbiota in health and respiratory disease. The method is reliable for low biomass samples due to prior amplification of the 16S rRNA gene but has limitations as species and certainly strain identification is not possible. However, the usage of metagenomic tools for the analyses of microbiome data from low biomass samples is not straight forward, and careful optimization is needed. In this work, we show that by validating StrainPhlAn 3 results with the data from bacterial cultures, the strain-level tracking of the respiratory microbiome is feasible despite the high content of host DNA being present when parameters are carefully optimized to fit low biomass microbiomes. This work further proposes that strain retention analyses are feasible, at least for more abundant species. This will help to better understand the longitudinal dynamics of the upper respiratory microbiome during health and disease.


6 July 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
CRCéline Rüttimann
Céline Rüttimann
ANAnnika Nissen-Kratzert
Annika Nissen-Kratzert
NMNadja Mostacci
Nadja Mostacci
NKNoëmi Künstle
Noëmi Künstle
AMAndrea Marten
Andrea Marten
OGOlga Gorlanova
Olga Gorlanova
Background: The effects of prenatal antibiotic exposure on respiratory morbidity in infancy and the involved mechanisms are still poorly understood. We aimed to examine whether prenatal antibiotic exposure in the third trimester is associated with nasal microbiome and respiratory morbidity in infancy and at school age, and whether this association with respiratory morbidity is mediated by the nasal microbiome.Methods: We performed 16S ribosomal RNA gene sequencing (regions V3–V4) on nasal swabs obtained from 296 healthy term infants from the prospective Basel–Bern birth cohort (BILD) at age 4–6 weeks. Information about antibiotic exposure was derived from birth records and standardised interviews. Respiratory symptoms were assessed by weekly telephone interviews in the first year of life and a clinical visit at age 6 years. Structural equation modelling was used to test direct and indirect associations accounting for known risk factors.Results: α-Diversity indices were lower in infants with antibiotic exposure compared to nonexposed infants (e.g.Shannon index p-value 0.006). Prenatal antibiotic exposure was also associated with a higher risk of any, as well as severe, respiratory symptoms in the first year of life (risk ratio 1.38, 95% CI 1.03–1.84; adjusted p-value (padj)=0.032 and risk ratio 1.75, 95% CI 1.02–2.97; padj=0.041, respectively), but not with wheeze or atopy in childhood. However, we found no indirect mediating effect of nasal microbiome explaining these clinical symptoms.Conclusion: Prenatal antibiotic exposure was associated with lower diversity of nasal microbiome in infancy and, independently of microbiome, with respiratory morbidity in infancy, but not with symptoms later in life.